Orchid Pharma Limited

ORCHPHARMA

INE191A01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:40:48 2024-05-16 EDT			5-day change	1st Jan Change
1,080 ^INR	-1.66%		+4.65%	+51.65%

04-12	Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director	CI
02-23	Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention	CI

Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer

December 14, 2023 at 02:39 am

Orchid Pharma Limited announced that Ms. Marina Peter has resigned from the position of Company Secretary and Compliance officer of the Company with effect from December 12, 2023.

Latest news about Orchid Pharma Limited

Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director	04-12	CI
Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention	02-23	CI
Transcript : Orchid Pharma Limited, Q3 2024 Earnings Call, Feb 09, 2024	02-09
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep'	01-30	CI
Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer	12-16	CI
Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer	12-14	CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-04	CI
Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent)	23-10-20	CI
Orchid Pharma Ties Up with GARDP to Manufacture Antibiotic for Certain Gram-Negative Infections	23-09-12	MT
Orchid Pharma Limited Enters into Manufacturing Sub License Agreement with Global Antibiotic Research & Development Partnership	23-09-12	CI
Orchid Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Orchid Pharma Raises INR4 Billion Via Qualifed Institutional Placement	23-06-28	MT
Orchid Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-10	CI
CARE Upgrades Rating on Orchid Pharma's Long-term Bank Financing to BBB; Outlook Stable	23-02-09	MT
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-09	CI
Orchid Pharma Limited Announces Demise of Arun Kumar Dhanuka, Non-Executive & Non-Independent Director	23-02-01	CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Orchid Pharma : UK drugs regulator to halt approvals for Indian clinical trials firm	16-07-01	RE

Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,080 INR

Average target price

1,130 INR

Spread / Average Target

+4.58%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORCHID PHARMA LIMITED	+51.65%	668M
ELI LILLY AND COMPANY	+32.36%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.60%	367B
MERCK & CO., INC.	+20.07%	334B
ABBVIE INC.	+6.04%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.27%	171B

Other Pharmaceuticals